Part 2 - Case Discussion

Brian A. Jonas, MD, PhD, FACP, presents the case of patient “C.O.” to fellow faculty members Daniel A. Pollyea, MD, MS, and Gabriel N. Mannis, MD. The virtual roundtable panel discusses unique features of the case and explores hypothetical variations of the circumstances, as well as offering insights into how the latest data from clinical trials may impact the future of treatment for patients with acute myeloid leukemia (AML).

Click here to learn more by viewing Part 3 - Case Discussion & Wrap-up.

Disclosures:

Brian A. Jonas, MD, PhD, FACP
Consulting Fees: AbbVie, Genentech, GlycoMimetics, Jazz, Takeda
Contracted Research: 47, AbbVie, Amgen, AROG, Celgene, Daiichi-Sankyo, Forma, Genentech/Roche, GMI, Hanmi, Jazz, Pfizer, PCYC
Travel Reimbursement: AbbVie

Gabriel N. Mannis, MD
Consulting Fees: AbbVie, Agios, BMS/Celgene, Genentech, Pfizer
Contracted Research: Gilead/Forty Seven, Glycomimetics, Jazz

Daniel A. Pollyea, MD, MS
Consulting Fees: Celgene, Abbvie, Genentech, Novartis, Karyopharm, Syndax, BMS
Other: Takeda, Syros, Kiadis, Foghorn, Aprea, Gilead, Amgen, Astellas

References:

  1. Ghandili et al. Blood Advances. 2020;4(23):5936-5941.
  2. https://www.nccn.org/covid-19/pdf/COVID-19_Vaccination_Guidance_V1.0.pdf
  3. https://www.cdc.gov/coronavirus/2019-ncov/index.html
  4. https://www.hematology.org/covid-19
  5. https://www.asco.org/asco-coronavirus-information